More recently, research on this new GLP-1 analog has gradually expanded into other areas, including diabetes, chronic kidney disease, cardiovascular disease, NASH, and Alzheimer’s disease (Knudsen and Lau, 2019). This evidence concerns the gene GLP1R and cardiovascular disorder.